Results 131 to 140 of about 149,070 (296)

Urolithin A, a Diet‐Derived Gut Microbial Metabolite Against Pulmonary Hypertension Identified via Molecular Docking, Molecular Dynamics and Surface Plasmon Resonance

open access: yesFood Safety and Health, EarlyView.
Urolithin A, a gut microbial metabolite, binds TNF to suppress proliferation, inflammation, and oxidative stress, offering a promising microbe‐derived therapeutic avenue for pulmonary hypertension. ABSTRACT Pulmonary hypertension (PH) is a complex and multifactorial disease that poses a significant clinical challenge.
Yujie Qu   +8 more
wiley   +1 more source

Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study) [PDF]

open access: green, 2023
Koji Ando   +27 more
openalex   +1 more source

Metastatic Cutaneous Adnexal Carcinoma of the Head and Neck With Durable Response to an Aromatase Inhibitor Combined With a Cyclin‐Dependent Kinase 4/6 Inhibitor

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Cutaneous adnexal carcinomas are a very rare group of cancers arising from appendageal structures of the skin. More than half occur in the head and neck region. No standard treatments exist for metastatic disease. Methods A 48‐year‐old postmenopausal female presented with an enlarging scalp lesion.
Nilesh Kapoor   +3 more
wiley   +1 more source

Different Pattern of Treatment Failure After Chemoradiation Between p16+ and p16− Patients Affected by Oropharyngeal Carcinoma

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Oropharyngeal cancer (OPC) exhibits distinct clinical behaviors according to HPV/p16 status and smoking exposure. While HPV‐positive OPC generally shows superior survival, differences in recurrence patterns remain unclear. Methods A retrospective multicenter analysis of 674 AJCC VII edition Stage III–IVa/b OPC patients treated with ...
Riccardo Gili   +16 more
wiley   +1 more source

Additional file 5: of Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment

open access: green, 2018
Nathan Ungerleider   +6 more
openalex   +1 more source

<i>TP53</i> mutation status and Nutlin-3a sensitivity of ovarian cancer cell lines.

open access: green, 2015
K. Crane Erin   +8 more
openalex   +2 more sources

Genetic, Surgical and Oncological Approach to Breast Cancer, with <i>BRCA1, BRCA2, CDH1, PALB2, PTEN</i> and <i>TP53</i> Variants

open access: diamond, 2022
Aslı Subaşıoğlu   +4 more
openalex   +1 more source

Home - About - Disclaimer - Privacy